Genmab A/S
Genmab A/S Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
2 of 3 strong
The short version
- Genmab expects continued strong revenue growth, with Q1 2026 revenue up 25%, driven by momentum across their portfolio, including EPKINLY and product sales. - Genmab expects continued revenue growth in 2026, targeting approximately 14% total revenue increase driven by key products like EPKINLY and their oral portfolio.
From Genmab A/S's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Genmab expects continued strong revenue growth, with Q1 2026 revenue up 25%, driven by momentum across their portfolio, including EPKINLY and product sales.
- They forecast 14% total revenue growth for 2026, supported by expanding portfolio and market opportunities.
- Planned investments in late-stage development (petosemtamab, arenas) and launch readiness will continue, supporting multiple potential product launches.
- They anticipate sustained revenue growth through disciplined prioritization, operating discipline, and scalability.
- The rapid enrollment in Phase III trials (e.g., RAINFALL 02 for Rina-S) is expected to accelerate pivotal data availability and support future product launches.
2 more points from Genmab A/S's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Genmab A/S said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Genmab is making significant strategic investments to advance late-stage development programs, specifically for petosemtamab and Rina-S.
- Investments are also directed toward launch readiness activities to support multiple potential product launches.
- The investments remain fully aligned with the company's capital allocation priorities, aiming to translate antibody science into meaningful clinical breakthroughs and sustainable shareholder value.
- Despite these strategic investments, Genmab has grown operating profit by 23%, signaling disciplined capital management.
- The company is committed to deleveraging, targeting gross leverage below 3x by the end of 2027 while maintaining balance sheet strength and flexibility.
2 more points from Genmab A/S's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Genmab A/S said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Genmab A/S's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Arthneeti Pro · Annual
Genmab A/S and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Genmab A/S Q2 FY26 results?
- Genmab expects continued strong revenue growth, with Q1 2026 revenue up 25%, driven by momentum across their portfolio, including EPKINLY and product sales. - Genmab expects continued revenue growth in 2026, targeting approximately 14% total revenue increase driven by key products like EPKINLY and their oral portfolio.
What is Genmab A/S share price analysis?
Genmab A/S currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 20.4 with a market cap of $17,370. Investors should review the full earnings analysis for detailed insights.
Is Genmab A/S planning capital expenditure?
- Genmab is making significant strategic investments to advance late-stage development programs, specifically for petosemtamab and Rina-S.
Keep Genmab A/S on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.